1. Home
  2. ALDX vs IMRX Comparison

ALDX vs IMRX Comparison

Compare ALDX & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$1.57

Market Cap

317.7M

Sector

Health Care

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$5.50

Market Cap

340.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALDX
IMRX
Founded
2004
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.7M
340.7M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
ALDX
IMRX
Price
$1.57
$5.50
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$5.50
$17.20
AVG Volume (30 Days)
6.0M
752.7K
Earning Date
05-13-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
40.43
37.75
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$1.10
52 Week High
$6.18
$10.08

Technical Indicators

Market Signals
Indicator
ALDX
IMRX
Relative Strength Index (RSI) 28.62 57.12
Support Level $1.07 $5.34
Resistance Level $5.75 $5.80
Average True Range (ATR) 0.21 0.28
MACD 0.04 0.04
Stochastic Oscillator 21.88 89.13

Price Performance

Historical Comparison
ALDX
IMRX

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: